JAGUAR HEALTH, INC. Earnings Per Share (Basic)
JAGUAR HEALTH, INC. (JAGX) reported Earnings Per Share (Basic) of -$15.70 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-19
- JAGUAR HEALTH, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$15.70.
- JAGUAR HEALTH, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$13.60.
- JAGUAR HEALTH, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$4.38.
- JAGUAR HEALTH, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$6.28.
- JAGUAR HEALTH, INC. earnings per share, basic for fiscal 2025 was -$22.97.
- JAGUAR HEALTH, INC. earnings per share, basic for fiscal 2024 was -$130.69.
- JAGUAR HEALTH, INC. earnings per share, basic for fiscal 2023 was -$2678.17.
- JAGUAR HEALTH, INC. earnings per share, basic for fiscal 2022 was -$36.18.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$15.70 10-Q · filed 2026-08-19 | -$35.11 10-Q · filed 2026-08-19 | -$19.44 derived: net income ÷ weighted average shares · filed 2026-08-19 | -$25.77 derived: net income ÷ weighted average shares · filed 2026-08-19 | ||||
| 2026-03-31 | -$13.60 10-Q · filed 2026-05-20 | -$10.39 derived: net income ÷ weighted average shares · filed 2026-05-20 | -$16.26 derived: net income ÷ weighted average shares · filed 2026-05-20 | -$27.25 derived: net income ÷ weighted average shares · filed 2026-08-19 | ||||
| 2025-12-31 | -$4.38 derived: net income ÷ weighted average shares · filed 2026-04-07 | -$9.60 derived: net income ÷ weighted average shares · filed 2026-04-07 | -$18.90 derived: net income ÷ weighted average shares · filed 2026-08-19 | -$22.97 10-K · filed 2026-04-07 | ||||
| 2025-09-30 | -$6.28 10-Q · filed 2025-11-14 | -$25.82 derived: net income ÷ weighted average shares · filed 2026-08-19 | -$22.61 10-Q · filed 2025-11-14 | -$74.29 derived: net income ÷ weighted average shares · filed 2026-08-19 | ||||
| 2025-06-30 | -$358.94 10-Q · filed 2026-08-19 | -$10.26 10-Q · filed 2025-08-14 | -$937.26 10-Q · filed 2026-08-19 | -$26.78 10-Q · filed 2025-08-14 | -$140.74 derived: net income ÷ weighted average shares · filed 2026-08-19 | -$157.67 derived: net income ÷ weighted average shares · filed 2026-08-19 | ||
| 2025-03-31 | -$584.45 10-Q · filed 2026-05-20 | -$16.70 10-Q · filed 2025-05-15 | -$64.99 derived: net income ÷ weighted average shares · filed 2026-05-20 | -$90.52 derived: net income ÷ weighted average shares · filed 2026-05-20 | -$34.74 derived: net income ÷ weighted average shares · filed 2026-05-20 | |||
| 2024-12-31 | -$16.28 derived: net income ÷ weighted average shares · filed 2026-04-07 | -$40.18 derived: net income ÷ weighted average shares · filed 2026-04-07 | -$19.27 derived: net income ÷ weighted average shares · filed 2026-04-07 | -$130.69 10-K · filed 2026-04-07 | ||||
| 2024-09-30 | -$26.29 10-Q · filed 2025-11-14 | -$1.05 10-Q · filed 2024-11-13 | -$9.80 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$150.72 10-Q · filed 2025-11-14 | -$4.89 10-Q · filed 2024-11-13 | -$44.56 derived: net income ÷ weighted average shares · filed 2025-11-14 | ||
| 2024-06-30 | -$2.66 10-Q · filed 2025-08-14 | -$4.04 10-Q · filed 2024-08-13 | -$7.80 10-Q · filed 2025-08-14 | -$15.93 10-Q · filed 2024-08-13 | -$27.77 derived: net income ÷ weighted average shares · filed 2025-08-14 | -$42.48 derived: net income ÷ weighted average shares · filed 2025-08-14 | ||
| 2024-03-31 | -$87.12 10-Q · filed 2025-05-15 | -$0.06 10-Q · filed 2024-05-14 | $65.71 derived: net income ÷ weighted average shares · filed 2025-05-15 | $366.45 derived: net income ÷ weighted average shares · filed 2025-05-15 | -$1926.26 derived: net income ÷ weighted average shares · filed 2025-05-15 | |||
| 2023-12-31 | $13.77 derived: net income ÷ weighted average shares · filed 2025-03-31 | $105.87 derived: net income ÷ weighted average shares · filed 2025-03-31 | $3317.52 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$2678.17 10-K · filed 2025-03-31 | -$1.79 10-K · filed 2024-04-01 | |||
| 2023-09-30 | -$22.50 10-Q · filed 2024-11-13 | -$0.38 10-Q · filed 2023-11-14 | -$62.32 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$132.49 10-Q · filed 2024-11-13 | -$2.21 10-Q · filed 2023-11-14 | -$20.55 derived: net income ÷ weighted average shares · filed 2024-11-13 | ||
| 2023-06-30 | -$41.35 10-Q · filed 2024-08-13 | -$0.69 10-Q · filed 2023-08-14 | -$128.12 10-Q · filed 2024-08-13 | -$2.14 10-Q · filed 2023-08-14 | -$12.98 derived: net income ÷ weighted average shares · filed 2024-08-13 | -$20.20 derived: net income ÷ weighted average shares · filed 2024-08-13 | ||
| 2023-03-31 | -$2.39 10-Q · filed 2024-05-14 | -$5.58 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$11.39 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$17.41 derived: net income ÷ weighted average shares · filed 2024-05-14 | ||||
| 2022-12-31 | -$3.83 derived: net income ÷ weighted average shares · filed 2024-04-01 | -$11.83 derived: net income ÷ weighted average shares · filed 2024-04-01 | -$19.79 derived: net income ÷ weighted average shares · filed 2024-04-01 | -$36.18 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | -$8.83 10-Q · filed 2023-11-14 | -$0.12 10-Q · filed 2022-11-14 | -$17.61 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$36.62 10-Q · filed 2023-11-14 | -$0.49 10-Q · filed 2022-11-14 | $1.71 derived: net income ÷ weighted average shares · filed 2023-11-14 | ||
| 2022-06-30 | -$8.77 10-Q · filed 2023-08-14 | -$0.12 10-Q · filed 2022-08-22 | -$29.51 10-Q · filed 2023-08-14 | -$0.40 10-Q · filed 2022-08-22 | $0.97 derived: net income ÷ weighted average shares · filed 2023-08-14 | $2.61 derived: net income ÷ weighted average shares · filed 2023-08-14 | ||
| 2022-03-31 | -$23.10 10-Q · filed 2023-05-15 | -$0.40 10-Q · filed 2022-05-10 | $0.50 derived: net income ÷ weighted average shares · filed 2023-05-15 | $1.60 derived: net income ÷ weighted average shares · filed 2023-05-15 | $6.09 derived: net income ÷ weighted average shares · filed 2023-05-15 | |||
| 2021-12-31 | $0.11 derived: net income ÷ weighted average shares · filed 2023-03-24 | $0.63 derived: net income ÷ weighted average shares · filed 2023-03-24 | $3.10 derived: net income ÷ weighted average shares · filed 2023-03-24 | -$88.22 10-K · filed 2023-03-24 | -$1.18 10-K · filed 2022-03-11 | |||
| 2021-09-30 | -$0.27 10-Q · filed 2022-11-14 | -$0.58 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$0.87 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | -$0.31 10-Q · filed 2022-08-22 | -$0.10 10-Q · filed 2021-08-13 | -$0.60 10-Q · filed 2022-08-22 | -$0.20 10-Q · filed 2021-08-13 | ||||
| 2021-03-31 | -$0.28 10-Q · filed 2022-05-10 | |||||||
| 2020-12-31 | -$3.00 10-K · filed 2022-03-11 | |||||||
| 2020-09-30 | -$0.62 10-Q · filed 2021-11-17 | -$3.09 10-Q · filed 2021-11-17 | ||||||
| 2020-06-30 | -$0.44 10-Q · filed 2021-08-13 | -$0.97 10-Q · filed 2021-08-13 | ||||||
| 2018-09-30 | -$0.51 10-Q · filed 2018-11-19 | -$1.91 10-Q · filed 2018-11-19 | ||||||
| 2018-03-31 | -$0.05 10-Q · filed 2018-05-15 | |||||||
| 2017-09-30 | $1.29 10-Q · filed 2018-11-19 | $0.09 10-Q · filed 2017-11-20 | -$0.94 10-Q · filed 2018-11-19 | -$0.06 10-Q · filed 2017-11-20 | ||||
| 2017-03-31 | -$0.33 10-Q · filed 2018-05-15 | |||||||
| 2016-09-30 | -$0.30 10-Q · filed 2017-11-20 | -$1.07 10-Q · filed 2017-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |